PHASE I & PHASE I/II CLINICAL TRIALS FOR TREATMENT OF COVID-19 ASSOCIATED ARDS BY AV-001, A NOVEL THERAPEUTIC TARGETING VASCULAR ENDOTHELIUM
$6,354,825FY2021Defense Health AgencyDOD
Vasomune Therapeutics Inc
Investigators
View source on USAspending →PHASE I & PHASE I/II CLINICAL TRIALS FOR TREATMENT OF COVID-19 ASSOCIATED ARDS BY AV-001, A NOVEL THERAPEUTIC TARGETING VASCULAR ENDOTHELIUM · GrantIndex